Xenetic Biosciences Inc (XBIO)

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell LymphomaJune 4, 2026 8:40 AM
ACCESS NewswireCompany evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported strong positive preclinical results demonstrating significantly enhanced anti-tumor activity of anti-CD-19 CAR T cells when combined with DNase I in multiple preclinical models of hematologic cancersInvestigator initiated study to be conducted at Tel-Aviv Sourasky Medical Center ("Sourasky Center")FRAMINGHAM, MA / ACCESS Newswire / June 4, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an exploratory clinical study of a combination systemic DNase I with anti-CD19 CAR T Cells in large B cell lymphoma (LBCL) patients. This approval follows positive preclinical results that demonstrated significant improvement of CAR T cell expansion and persistence and functionality when combined with DNase I. This combination therapy resulted in improved tumor control, delayed relapse and prolonged survival across multiple preclinical models of leukemia and lymphoma.Under the approved clinical study protocol, 12 LBCL patients with stable or progressive disease prior to lymphodepletion therapy are intended to be treated with CAR T cells targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) in combination with DNase I (50-ml IV infusion dose, 1.0 mg/kg IV on Days 0,3,6,10 and 15 after CAR T cells infusion). Clinical efficacy is intended to be evaluated by the Objective Response Rate (ORR) at 1 and 3 months post CAR T infusion, duration of response (DOR), disease control rate (DCR) and overall survival (OS) at 12 months post CAR T cells infusion. We believe the study has the potential for a translational component with a complex assessment of biomarker response and analysis of anti-CD19 CAR T expansion and persistence.Dr. Ron Ram, Professor of Medicine and Head of the Bone Marrow Transplantation Unit at the Sourasky Center, has initiated the study as the principal investigator and all work is intended to be conducted at Sourasky Center in Israel."Progression of LBCL is the major obstacle for the success of CAR T therapies, with approximately 50-60% of the patients relapsing in the first year, and approximately 30-45% within 3 months after CAR T infusion, depending on the CAR T product used. While patients with partial or complete response before CAR T infusion have a 1-year progression free survival of approximately 60-80%, those with stable or progressive disease at the time of CAR T infusion have a dismal 1-year progression free survival of approximately 20-30%," commented Dr. Ram "Preclinical data generated over the last few years confirms that accumulation of cell-free chromatin and neutrophil extracellular traps (NETs) within the tumor microenvironment represents a general mechanism of CAR T-cell dysfunction through induction of exhaustion, immunosuppression and impaired expansion and this mechanism is targetable by DNase I. The goal of this clinical study is to improve clinical response by administering DNase I to abrogate the negative effects of cell-free chromatin and NETs on the performance of immune system and CAR T cells."Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute and a member of Xenetic's Scientific Steering Committee, added, "CAR T cell treatment induces intensive tumor-cell death and inflammation within the tumor over a short period of time, resulting in massive release of cell-free chromatin and neutrophil extracellular traps (NETs) into the tumor microenvironment. This extracellular DNA burden acts as a major stress factor that accelerates CAR T cell dysfunction and exhaustion, creating a potent negative feedback loop that limits durable efficacy. DNase I disrupts this loop by degrading cell-free chromatin and NETs, thereby improving CAR T cell fitness, preserving cytotoxicity and functional persistence and reducing exhaustion markers, including PD-1, LAG-3, and TIM-3. In our preclinical models, these effects were associated with more durable tumor control following repeated tumor re-challenge, with no tumor regrowth observed in DNase I-treated animals under conditions where tumor progression occurred in the control group. Importantly, unlike conventional strategies that seek to improve CAR T cells primarily through additional cell engineering, our approach is designed to improve the battlefield itself by removing key extracellular barriers to CAR T cell function. We believe the planned study at Tel Aviv Sourasky Medical Center is particularly meaningful given the institution's longstanding leadership in CAR T-cell therapy and immuno-oncology innovation, both in Israel and internationally. As a pioneer in the development, clinical validation and early adoption of advanced cellular therapies, Sourasky Center combines elite clinical expertise, cutting-edge translational research infrastructure and a proven ability to rapidly translate scientific discoveries into innovative patient treatments, making it an ideal institution to lead this exploratory clinical study."About Tel Aviv Sourasky Medical CenterThe Tel Aviv Sourasky University Medical Center is the second-largest hospital in Israel. It provides healthcare services to approximately 4 million residents of the Tel Aviv metropolitan area (Gush Dan) and serves citizens from all over the country. The Tel Aviv Medical Center is a municipal-government hospital that comprises four hospitals: Ichilov General Hospital, Lis Maternity and Women's Hospital, Dana-Dwek Children's Hospital, and the Ida Sourasky Rehabilitation Hospital. In 2022, the Sylvan Adams Emergency Medicine Hospital was inaugurated. At the end of 2023, rehabilitation services were significantly expanded with the opening of BeShilam - the Rehabilitation Hospital for War Casualties.About Xenetic BiosciencesXenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.For more information, please visit the Company's website at?www.xeneticbio.com?and connect on?X,?LinkedIn, and?Facebook.Forward-Looking StatementsThis press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding planned treatments under clinical study protocol 12 LBCL and intended evaluations of the clinical efficacy thereof, the Company's belief that clinical study protocol 12LBCL has the potential for a translational component with a complex assessment of biomarker response and analysis anti-CD19 CAR T expansion and persistence, where work related to the study is intended to be conducted,, our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.Contact:JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.comSOURCE: Xenetic Biosciences, Inc.View the original press release on ACCESS NewswireOriginal: Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and SurvivalJune 1, 2026 9:02 AM
ACCESS NewswireNew preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer modelsFindings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancersData to be presented today as a poster presentation at the ASCO 2026 annual meetingFRAMINGHAM, MA / ACCESS Newswire / June 1, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced positive preclinical data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. Presentation Details:Session Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster Session)Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR-T cell function and antitumor efficacyPoster Board: 410Presentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDTPresenter: Alexey V. Stepanov, PhDThe poster presentation, titled "Targeting cfDNA and NETs with DNase I Augments CAR T-Cell Function and Antitumor Efficacy," highlights evidence that extracellular DNA and neutrophil extracellular traps (NETs) act as key drivers of CAR-T cell exhaustion and persistence, leading to therapeutic failure. The findings demonstrate that DNase I degrades these immunosuppressive barriers and restores CAR-T functionality.In preclinical studies, DNase I efficiently degraded extracellular DNA, preserved CAR-T cell effector function, improved CD8-positive T cell ratios and reduced expression of exhaustion markers including PD-1, LAG-3 and TIM-3 across multiple rounds of tumor rechallenge in vitro.In vivo, DNase I significantly enhanced CAR-T cell expansion and persistence following infusion in both NALM-6 B cell leukemia and Raji Burkitt lymphoma xenograft models. Combination therapy with DNase I resulted in improved tumor control, delayed relapse upon rechallenge and prolonged survival compared to CAR T-cell therapy alone.The poster also includes translational observations from a pediatric patient with highly refractory Burkitt lymphoma, where DNase I co-administration was associated with marked CAR-T cell expansion and progressive reduction in tumor burden following prior CAR-T cell failure."These findings continue to strengthen the growing body of evidence implicating extracellular DNA and NETs as important contributors to immune suppression and therapeutic resistance in cancer," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic Biosciences. "We believe these data highlight the potential for DNase I to serve as a differentiated adjunctive immuno-oncology strategy capable of improving CAR T-cell persistence and durability across difficult-to-treat hematologic malignancies."The findings further support Xenetic's broader DNase-based immuno-oncology platform designed to improve outcomes of existing cancer therapies, including immunotherapies and cell therapies, through targeting NET-driven immune suppression within the tumor microenvironment.For more information about the ASCO Annual Meeting 2026, please visit www.asco.org.About Xenetic BiosciencesXenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.Forward-Looking StatementsThis press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, our focus on advancing DNase into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors, the potential of DNase I as a transformative adjunct therapy for CAR-T treatment and to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models and new findings supporting continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers and continuing to strengthen the body of evidence implicating extracellular DNA and NETs as important contributors to immune suppression and therapeutic resistance in cancer. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.comSOURCE: Xenetic Biosciences, Inc.View the original press release on ACCESS NewswireOriginal: Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology PlatformMay 13, 2026 8:05 AM
ACCESS NewswireAdvancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical developmentStrengthened financial profile with continued royalty revenue growthEnded first quarter 2026 with approximately $7.3 million in cash while continuing evaluation of strategic alternatives to maximize shareholder valueFRAMINGHAM, MA / ACCESS Newswire / May 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corporate update on the advancement of its innovative DNase oncology platform.Recent HighlightsGenerated robust translational data supporting the DNase I platform across multiple oncology settingsCompleted process improvement and analytical development activities supporting future clinical manufacturing readinessEstablished translational and biomarker insights intended to help inform and de-risk future clinical trial designCollaboration partner received approval from Israeli Ministry of Health to conduct investigator-initiated exploratory study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma"We entered 2026 with a clear focus on advancing the translational, manufacturing and clinical foundation of our DNase I platform while maintaining financial discipline," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. "During the quarter, we achieved important progress across investigator-initiated studies, translational research and manufacturing readiness activities. We believe the growing body of translational evidence supporting NET-targeting approaches, combined with the expanding understanding of NETs as drivers of tumor progression, immune suppression and therapy resistance, continues to strengthen the potential opportunity for DNase I as a differentiated adjunctive immuno-oncology therapy across multiple cancer settings."Xenetic's proprietary DNase technology is being developed as a potential adjunctive therapeutic approach designed to improve the effectiveness of existing cancer treatments, including immunotherapies, through the targeting of NETs, which are increasingly recognized as key drivers of immune suppression and therapeutic resistance within the tumor microenvironment.Summary of Financial Results for First Quarter 2026Royalty revenue for the three months ended March 31, 2026 increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period, primarily driven by increased royalty payments recognized under the Company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd.Research and development expenses for the three months ended March 31, 2026 decreased approximately 25% to approximately $0.7 million from approximately $0.9 million for the comparable prior year period, primarily due to lower preclinical and exploratory study costs, partially offset by increased manufacturing development efforts supporting the Company's DNase I program.General and administrative expenses for the three months ended March 31, 2026 decreased by approximately 1.4%, to approximately $0.6 million from approximately $0.7 million in the comparable quarter in 2025. The decrease was primarily due to a decrease in personnel costs and share-based expenses related to our interim Chief Executive Officer substantially offset by an increase in legal expenses related to our strategic review process during the first quarter of 2026 compared to the same period in 2025.Net loss for the quarter ended March 31, 2026 decreased approximately 49% to approximately $0.5 million, compared to approximately $0.9 million for the same period in 2025.The Company ended the first quarter of 2026 with approximately $7.3 million in cash and cash equivalents, compared to approximately $7.9 million as of December 31, 2025.About Xenetic BiosciencesXenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.Forward-Looking StatementsThis press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding future clinical development, manufacturing readiness and trial design, our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, our belief regarding strengthening the potential opportunity for DNase I as an adjunctive therapy across multiple cancer settings and our focus on advancing DNase into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.Contact:JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.comSOURCE: Xenetic Biosciences, Inc.View the original press release on ACCESS NewswireOriginal: Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsMarch 13, 2026 8:00 AM
ACCESS NewswireEncouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancersStrategic focus on investigator-initiated exploratory studies and institutional collaborationsContinued progress toward IND-enabling activities for DNase I programEnded the year with $7.9 million of cash to fund operationsFRAMINGHAM, MA / ACCESS Newswire / March 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2025. Recent HighlightsExpanded and presented preclinical and translational evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression and highlighting the therapeutic potential of Deoxyribonuclease (DNase) -based interventions;Progressed investigator-initiated exploratory studies in Israel evaluating DNase I in combination with standard-of-care and immunotherapy platforms, including:Ongoing pancreatic ductal adenocarcinoma (PDAC) study;Proposed large B-cell lymphoma (LBCL) study in combination with Chimeric Antigen Receptor (CAR) T cell therapy;Advanced clinical manufacturing activities for DNase I toward Investigational New Drug (IND) application;Current focus on mechanism-of-action and translational research studies supported by encouraging CAR-T proof-of-concept studies with Scripps Research; andPursuing strategic alternatives to maximize shareholder value."During 2025, we continued to advance our DNase-based technology toward Phase 1 clinical development while making steady progress across scientific, operational and strategic fronts," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. "We strengthened the evidence linking NETs to cancer progression and the therapeutic promise of DNase-based strategies, advanced multiple investigator-initiated studies and progressed toward IND-enabling activities. We believe these efforts position the Company well as we move through 2026, while remaining disciplined in our use of capital and focused on creating long-term shareholder value."Xenetic continues to advance its DNase-based technology toward Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. During 2025, the Company completed preclinical studies evaluating DNase I in combination with chemotherapy, immunotherapies and CAR-T approaches across both solid and hematologic cancer models. Data generated from these studies are informing ongoing translational work and manufacturing activities as the Company progresses toward U.S. IND submission.Summary of Financial Results for Fiscal Year 2025
Net loss for the year ended December 31, 2025 was approximately $2.7 million, reflecting investment in the Company's most promising scientific programs. Royalty revenue from the Company's sublicense with Takeda Pharmaceuticals Co. Ltd increased approximately 19% to $3.0 million in the year ended December 31, 2025 from $2.5 million for the year ended December 31, 2024 primarily due to royalty payments received from certain countries. Research and development expenses for the year ended December 31, 2025 decreased by approximately $0.2 million, or 7%, to $3.1 million from $3.3 million in the prior year period. Research and development costs for the year ended December 31, 2024 included a $0.7 million impairment charge that did not reoccur in 2025. This decrease was substantially offset by increased spending in connection with the Company's DNase process development efforts. General and administrative expenses for the year ended December 31, 2025 were $2.7 million, decreasing by approximately $0.7 million, or 20%, compared to the prior year. This decrease was primarily due to certain severance and benefits expensed during the year ended December 31, 2024 in connection with a separation agreement entered into during the second quarter of 2024 with our former Chief Executive Officer.The Company ended the year with approximately $7.9 million of cash, representing an increase of approximately $1.7 million compared to the prior year-end, primarily due to net proceeds of approximately $4.0 million from an underwritten public offering completed in October 2025.About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding our belief that our efforts position the Company well as we move through 2026, while remaining disciplined in our use of capital and focused on creating long-term shareholder value, expectations regarding data generated informing ongoing translational work and manufacturing activities as the Company progresses toward U.S. IND submission, our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.CONTACT:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.comSOURCE: Xenetic Biosciences, Inc.View the original press release on ACCESS NewswireOriginal: Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

$18 +300% took 4 years to get back to $18

$15s cure to cancer 

$6 to $12 

What's the story here

Doing peek-a-boo with $5.00 today.

Ended the quarter with $7.8 million of cash to fund operations 

XBIO under $5

XBIO under $4

Xenetic Biosciences Inc NASDAQ: XBIO

GoSymbol lookup
Health Care : Biotechnology | Small Cap BlendCompany profile
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing its immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are weblike structures composed of extracellular chromatin coated with histones and other proteins. The Company is also developing its personalized Chimeric Antigen Receptor (CAR) T platform technology, XCART, to develop cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. It is also focused on developing its proprietary drug delivery platform, PolyXen, which uses the biological polymer polysialic acid (PSA) to prolong the drug's half-life and potentially improve the stability of therapeutic peptides and proteins.

whats going on over here?????? nice moves this year.

I like what’s developing here!

XBIO: Great price to invest here. Count me in.

Amazing patents. The stock was recently at $5.00/share. It is egregiously shorted, for no good reason, which means I'm coming in to own it. Heavily.

$XBIO
#XBIO

xbio 1.79 https://stockcharts.com/h-sc/ui?s=xbio

yesir you are correct good job

looks like nobody cares about this pile of poo

big new out everyone miss it ?

xbio news out !

I may move this money and cut my loses

XBIO is off the SHO list. I may reevaluate

Most sells all day today. Done for the day here will hopefully see some green next week. Enjoy the weekend

We need to get out of these 2s if we want to see any volume anytime soon it seems

This will run like crazy when MMs decide to cover their naked shorts. Until then we churn

XBIO: Technical Analysis - Epic Entry (chart)



$XBIO
#XBIO

XBIO: Reasons to invest into Xenetic Biosciences Inc

- ortex numbers
- extremely low float
- on the threshold list
- great patents
- good price point for growth
- low market cap (good for ownership)
- squeeze potential

$XBIO
#XBIO

XBIO: Great buy here at these levels

$XBIO
#XBIO

only 22% of the float worth of FTDs in early august. MMs have a ton of work to do

Come on volume!

Just picked up 1000

Short exempts were not that high today but volume was half of what it was yesterday. However Wednesday and Thursday were 1.3% and 4.3% of the float respectively. The extremely low volume today was ok because nobody is selling and shares are hard to locate. MMs are behind on delivering so soon they will be slapping the ask

If XBIO has another high short exempt day on this low volume it means MMs can't locate shares. It is already on the SHO list with lots of FTDs so MMs can't afford to get too behind on shares.
Remember the float is 8.89 million so the MMs soon will have to slap that ask hard.
APE STRONG

In for 10k shares

I actually forgot I still have shares in the 5s from a while back when I looked in my other account to see if anything cleared to buy yet. Lol

Whats the short interest over here against the float?

Im Holding a boat, will load another boat when i see some movement.

If short exempts are huge again this is going to explode. Shares are very hard to locate

Sold some to get a starter over here. Looks really interesting and actually if you look back in time this has been well over $400 per share. The company is in great shape, can’t wait to see how this plays out.

Sold some more junk yesterday. Thought I would get funds today but don't see any. Going to be a player over here Monday

FTDs from late July


Zero shares to borrow and 107% rate

LOAD THE BOAT!!!!!

Shares must be hard to locate

XBIO had an unusual amount of short exempts today on low volume. 370,000 short exempts. This could make a move soon.

Looking ti run here $$$$

We need green tomorrow

2.7 million FTDs in late July

Any thoughts on the S3 filing? This may hurt short term but long term
Outlook is good. The lender obviously has confidence in the company

Just slapped it for 1200 more. Enjoy the ride

Time to load up cheapies $$$$